Mukka Proteins Limited Holds 16th AGM on Sep 10, 2026, Discusses Financials and Re-appointments
Mukka Proteins Limited held its 16th AGM on September 10, 2026. The meeting reviewed financial statements for FY26 and discussed director re-appointments and borrowing limits. Key managerial personnel, including the MD & CEO, CFO, and COO, were proposed for re-appointment. Approval was also sought for related party transactions.
The announcement pertains to the procedural aspects of an AGM, including re-appointments and approvals of routine matters. It does not introduce any new significant business developments or financial outcomes that would materially impact the company's stock.
The announcement is a routine update on the proceedings of the Annual General Meeting and does not contain any specific financial performance indicators or forward-looking statements that would suggest a positive or negative sentiment.
Mukka Proteins Limited convened its 16th Annual General Meeting (AGM) on Thursday, September 10, 2026, conducted virtually via Video Conference (VC) / Other Audio Visual Means (OAVM). The meeting, which commenced at 3:00 P.M. IST and concluded at 4:26 P.M. IST, was held in accordance with circulars issued by the Ministry of Corporate Affairs (MCA) and the Securities and Exchange Board of India (SEBI).
The AGM was attended by all Directors, Key Managerial Personnel, and the Statutory Auditors. The proceedings included a review of the Audited Standalone and Consolidated Financial Statements for the Financial Year ended March 31, 2026, presented by the Whole-Time Director & CFO, Mr. Kalandan Mohammed Althaf. The Chairman, Mr. Karkala Shankar Balachandra Rao, also briefed the members on the company's operational performance and business developments.
Key agenda items included the re-appointment of directors retiring by rotation, namely Mr. Kalandan Mohammad Arif and Mrs. Umaiyya Banu. Special business items involved approving an increase in the overall borrowing limit under section 180(1)(c) of the Companies Act, 2013, and approving limits for the creation of mortgage or charge on assets under Section 180(1)(a). Additionally, the re-appointment of several Non-Executive Independent Directors (Mr. Karkala Shankar Balachandra Rao, Mr. Hamad Bava, Mr. Narendra Surendra Kamath) and key managerial personnel (Mr. Kalandan Mohammed Haris as Managing Director and CEO, Mr. Kalandan Mohammed Althaf as Whole-Time Director and CFO, and Mr. Kalandan Mohammad Arif as Whole-Time Director and COO) were proposed. The meeting also addressed the approval of material related party transactions with Atlantic Marine Products Private Limited, Progress Frozen and Fish Sterilization, Ullal Fish Meal and Oil Company, and Mangalore Fish Meal and Oil Company.
Shareholders had the opportunity to ask questions and express their views, which were addressed by the executive directors. The meeting concluded with the Chairman informing that the voting results would be declared upon receipt of the Scrutinizer's Report and would be uploaded on the company's website.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.